A Phase II Study of Enzalutamide Plus Dutasteride as First Line Treatment for Vulnerable Patients =/> 65 Years Old With Systemic Prostate Cancer.

Trial Profile

A Phase II Study of Enzalutamide Plus Dutasteride as First Line Treatment for Vulnerable Patients =/> 65 Years Old With Systemic Prostate Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Dutasteride (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Results (n=31) presented at the 42nd European Society for Medical Oncology Congress
    • 22 Aug 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
    • 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top